YOLFTbeta
Cellectis

Cellectis

ALCLS · PA · Healthcare / Biotechnology

1.06EUR-0.22 (-17.50%)

Price History

Full chart

Market Stats

Previous Close1.28
Open1.07
Day Range1.01 – 1.17
52-Week Range1.09 – 4.84
Volume1.98M
Market Cap126.30M
P/E (TTM)0.00
Forward P/E6.30
EPS-0.57
Dividend Yield0.00%
Beta2.77
50-Day Avg2.29
200-Day Avg2.95

About

Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Andre Choulika Ph.D.
  • Employees224
  • Headquarters8, rue de la Croix Jarry, Paris, France, 75013, France
  • Websitehttps://www.cellectis.com

Leadership

  • Dr. Andre Choulika Ph.D.Co-Founder, CEO & Director · b. 1965
  • Dr. David J. Sourdive Ph.D.Co-Founder, Deputy CEO, Executive VP of CMC & Manufacturing and Director · b. 1967
  • Mr. Arthur StrilCFO & Chief Business Officer · b. 1989
  • Valerie CrosPrincipal Financial Officer & Principal Accounting Officer
  • Mr. Jean Charles Epinat Ph.D.Chief Technological Officer
  • Dr. Philippe Duchateau Ph.D.Chief Scientific Officer · b. 1963
  • Ms. Marie-Bleuenn TerrierGeneral Counsel & Secretary of the Board of Directors · b. 1982
  • Pascalyne WilsonDirector of Communications
  • Ms. Kyung Nam-WortmanExecutive VP & Chief Human Resources Officer · b. 1970
  • Mr. Stephan Reynier M.Sc.Chief Regulatory & Pharmaceutical Compliance Officer · b. 1969

Financials

Income Statement

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue652.00K943.00K699.00K5.91M1.19M4.10M14.77M17.32M20.98M20.73M27.81M22.82M26.30M55.04M42.58M25.19M12.73M15.19M73.95M73.95M19.17M755.00K41.51M75.92M
Growth (%)-+44.63%-25.87%+744.78%-79.88%+245.23%+260.13%+17.26%+21.14%-1.20%+34.19%-17.97%+15.26%+109.30%-22.63%-40.85%-49.46%+19.32%+386.83%0.00%-74.08%-96.06%+5397.48%+82.92%
Cost of Revenue801.00K899.00K3.51M4.35M2.93M1.48M1.54M2.33M1.92M3.26M2.03M847.86K3.69M2.71M1.69M2.62M2.74M11.39M36.27M36.27M1.77M737.00K9.18M20.88M
Gross Profit-----2.62M13.23M14.99M19.06M17.47M25.78M21.97M22.61M52.34M40.90M22.57M9.99M3.80M37.67M37.67M17.40M18.00K41.51M55.04M
Gross Margin-----63.99%89.56%86.57%90.84%84.27%92.70%96.28%85.97%95.08%96.04%89.60%78.49%25.00%50.95%50.95%90.76%2.38%100.00%72.50%
Operating Expense-----10.41M18.02M28.49M34.31M42.78M51.92M102.59M28.99M82.87M104.86M115.22M115.08M127.35M123.11M123.11M107.06M97.32M101.06M97.05M
Operating Income------7.78M-4.80M-13.50M-15.25M-25.31M-26.14M-80.62M-6.38M-30.53M-63.96M-92.65M-105.09M-123.55M-85.44M-85.44M-89.67M-97.30M-59.55M-42.00M
Operating Margin------189.73%-32.48%-77.92%-72.68%-122.09%-93.98%-353.35%-24.25%-55.46%-150.20%-367.83%-825.47%-813.38%-115.54%-115.54%-467.72%-12887.68%-143.48%-55.32%
EBITDA------6.09M-3.20M-12.25M-12.98M-24.50M-20.76M1.17M4.11M-29.22M-65.03M-100.31M-85.91M-116.68M-75.62M-68.87M-71.23M-92.64M-9.46M-21.12M
EBITDA Margin------148.45%-21.66%-70.74%-61.87%-118.21%-74.62%5.13%15.64%-53.09%-152.72%-398.23%-674.80%-768.12%-102.26%-93.13%-371.56%-12269.67%-22.80%-27.82%
Net Income------4.36M171.23K-5.52M-10.72M-30.90M-29.45M-84.28M24.32K-22.46M-63.92M-99.37M-78.69M-90.69M-72.57M-86.28M-98.69M-101.06M-36.76M-70.35M
Net Income Margin------106.22%1.16%-31.87%-51.11%-149.05%-105.89%-369.38%0.09%-40.81%-150.10%-394.51%-618.12%-597.01%-98.14%-116.68%-514.78%-13385.30%-88.57%-92.66%
R&D-------11.42M16.37M15.95M25.10M34.44M17.52M57.30M74.56M79.23M76.57M92.04M86.95M86.95M97.50M87.65M90.54M97.33M
R&D as % of Total Revenue-------65.94%78.04%76.95%90.25%150.95%66.62%104.10%175.10%314.54%601.42%605.94%117.58%117.58%508.59%11608.74%218.13%128.20%
Interest Expense0000029.16K13.92K8.60K203.48K632.49K2.32M407.36K195.78K22.96K6.31K4.00K46.00K2.61M12.05M5.34M3.79M5.31M7.45M8.44M
Interest Expense % of Total Revenue0.00%0.00%0.00%0.00%0.00%0.71%0.09%0.05%0.97%3.05%8.35%1.79%0.74%0.04%0.01%0.02%0.36%17.16%16.29%7.22%19.75%702.91%17.96%11.11%

Balance Sheet

Currency: USD2002-12-312003-12-312004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets10.09M7.66M5.76M13.35M11.13M53.87M60.83M91.34M69.23M131.89M115.11M44.11M167.34M372.88M330.68M332.88M500.84M467.47M469.47M382.08M261.22M334.27M383.54M324.72M
Total Liabilities1.30M1.26M1.73M4.24M5.17M10.33M14.62M18.12M19.10M94.86M33.42M37.46M94.95M84.67M56.63M46.98M50.57M112.00M160.63M145.60M135.28M249.57M252.51M248.85M
Total Equity8.79M6.40M4.03M9.11M5.96M43.54M46.21M73.22M50.13M37.02M78.93M6.95M73.92M287.42M272.18M266.79M409.30M315.12M275.57M221.29M117.97M84.69M131.03M75.91M
Cash8.28M5.60M1.94M7.65M4.68M36.74M39.78M65.33M31.98M54.93M28.84M10.44M136.62M343.56M290.50M296.98M451.89M360.91M268.24M186.13M97.70M136.71M143.25M61.53M
Total Debt------1.82M2.62M1.82M69.08M5.67M5.61M4.48M2.17M1.76M34.00K1.35M47.61M111.30M102.24M82.85M85.06M91.46M90.73M
Net Debt------36.74M-37.97M-62.71M-30.16M14.15M-23.17M-4.82M-132.13M-341.38M-288.74M-296.95M-450.54M-313.30M-156.94M-83.90M-14.85M-51.65M-51.79M29.20M

Cash Flow

Currency: USD2004-12-312005-12-312006-12-312007-12-312008-12-312009-12-312010-12-312011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-391.00K--5.62M1.78M-7.05M-21.10M-13.19M-26.11M-25.63M50.74M3.54M-31.09M-52.33M-68.14M-69.14M-80.26M-104.56M-87.44M-24.75M22.99M-41.64M
Investing Cash Flow---316.39K-1.12M316.64K-5.69M-29.41M-6.10M-2.08M-1.65M-7.61M-50.50M1.78M35.62M-35.87M-54.34M7.28M-2.76M-15.51M-102.81M-30.69M
Financing Cash Flow231.00K5.85M247.00K34.79M4.05M30.91M-1.18M66.39M4.93M7.50M70.41M217.35M460.64K41.27M236.49M-3.86M27.32M47.52M1.15M82.86M89.11M-16.81M
Capital Expenditure1.36M353.00K479.00K147.26K790.71K713.51K6.66M4.25M5.49M1.91M430.47K4.25M13.34M2.66M4.89M12.96M46.26M19.74M2.44M1.07M3.84M2.46M
Free Cash Flow----5.77M988.39K-7.76M-27.76M-17.44M-31.60M-27.54M50.31M-715.02K-44.42M-54.98M-73.02M-82.10M-126.52M-124.31M-89.89M-25.82M19.15M-44.10M
Dividends Paid----------------000000
FCF to OCF---102.62%55.56%110.12%131.55%132.20%121.01%107.47%99.15%-20.21%142.90%105.08%107.17%118.74%157.64%118.88%102.79%104.34%83.28%105.90%
Dividend Paid to FCF----------------0.00%0.00%0.00%0.00%0.00%0.00%

Earnings

Report DateApr 28, 2014Jun 9, 2015Sep 8, 2015Nov 16, 2015Mar 14, 2016May 12, 2016Sep 8, 2016Nov 22, 2016Mar 6, 2017May 9, 2017Aug 3, 2017Nov 1, 2017Mar 12, 2018May 7, 2018Aug 1, 2018Nov 13, 2018Mar 11, 2019May 7, 2019Aug 7, 2019Nov 13, 2019Mar 4, 2020May 6, 2020Jul 22, 2020Nov 5, 2020Mar 4, 2021May 6, 2021Aug 5, 2021Nov 4, 2021Mar 3, 2022May 12, 2022Aug 4, 2022Nov 3, 2022Mar 8, 2023May 4, 2023Aug 3, 2023Nov 6, 2023Mar 13, 2024Apr 29, 2024Aug 6, 2024Nov 4, 2024Mar 13, 2025May 12, 2025Aug 4, 2025Nov 7, 2025Mar 19, 2026May 11, 2026Aug 6, 2026Nov 13, 2026
EPS Estimate-0.42----0.42-0.43-0.320.00-----0.57-0.61-0.48-0.48-0.70-0.59-0.54-0.73-0.68-0.58-0.66-0.52-0.65-0.68-0.60-0.55-1.10-0.64-0.68-0.54-0.81-0.37-0.39-0.37-0.32-0.35-0.29-0.27-0.17-0.23-0.12-0.14-0.25-0.21--
EPS Actual0.000.19-0.63-0.360.59-0.46-0.43-0.36-0.35-0.53-0.68-0.62-0.61-0.33-0.15-0.48-0.47-0.32-0.70-0.34-0.790.44-0.64-0.60-0.80-0.23-0.73-0.71-0.48-0.62-0.42-0.63-0.58-0.58-0.19-0.31-0.65-0.70-0.36-0.230.08-0.18-0.210.01-0.23-0.15-0.19-
Surprise100.00%---240.48%-6.98%-34.38%------7.56%45.90%69.50%0.94%32.84%45.53%-30.44%52.86%-15.66%175.19%2.77%-14.85%-22.33%66.15%-21.67%-29.09%56.36%3.13%38.24%-16.67%28.40%-56.76%51.28%16.22%-103.13%-100.00%-24.14%14.81%147.06%21.74%-74.41%103.58%11.05%28.42%--
Timing-After-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursAfter-hoursPre-market

Key Statistics & Ratios

Market Cap126.30M
Enterprise Value53.02M
Trailing P/E0.00
Forward P/E6.30
PEG Ratio0.00
Price / Sales1.98
Price / Book3.48
EPS-0.57
Book Value0.5018
Revenue (TTM)63.82M
Gross Profit (TTM)63.82M
EBITDA-46.68M
Profit Margin-102.34%
Operating Margin-340.69%
Return on Equity-94.54%
Return on Assets-11.67%
Shares Outstanding72.72M
Shares Float48.58M
Beta2.77
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Nov 1, 20112:1